Table 2 Characteristics of the patients treated for hepatitis C according to clinic model and treatment outcomes
From: Increasing Hepatitis C treatment uptake among HIV-infected patients using an HIV primary care model
Clinic model | Hepatology | HIV primary care | P value |
|---|---|---|---|
(n = 26) | (n = 48) | ||
Median age - years (range) | 44 (27–62) | 49 (19–61) | 0.18a |
Sex: Male (%) | 23 (88) | 38 (79) | 0.32b |
Race | |||
White | 21 | 32 | 0.44c |
Black | 4 | 13 | |
Other/unknown | 1 | 3 | |
Ethnicity | |||
Hispanic | 5 | 7 | 0.12c |
Not-Hispanic | 19 | 41 | |
Unknown | 2 | 0 | |
HIV risk factors | |||
Gay/bisexual | 8 | 21 | 0.008c |
Heterosexual | 5 | 14 | |
Intravenous drug use | 1 | 0 | |
Hemophilia | 3 | 0 | |
combination | 3 | 11 | |
Other/unknown | 6 | 2 | |
Median CD4+ cell count - cells/mm3 (range) | 375 (149–1179) | 522 (130–1142) | 0.02a |
Number with undetectable HIV load (%) | 22 (85) | 29 (83) | 0.88b |
Hepatitis C genotype2 | |||
Genotype 1/4 | 19 | 39 | 0.42b |
Genotype 2/3 | 7 | 9 | |
Median HCV load - log10 copies/mL (range) | 6.04 (5.1–7.7) | 6.41 (3.0–7.6) | 0.88a |
Liver biopsy scores 1 | |||
F0-2 | 8 | 12 | 0.37c |
F3,4 | 9 | 23 | |
Number with relapse after prior HCV treatment (%) | 5 (19) | 5 (11) | 0.29b |
Any neuropsychiatry history – % | 17 (65) | 23 (48) | 0.15b |
On any psychiatry medications - % | 11 (42) | 15 (31) | 0.34b |
Drugs or alcohol use within 3months of HCV treatment consideration | |||
No | 12 | 32 | 0.0001c |
Yes | 5 | 16 | |
Unknown | 9 | 0 | |
Median hemoglobin levels - g/dL (range) | 14.8 (11.1–16.9) | 14.5(12.1–16.6) | 0.17a |
Median platelet count -1000/mm3 (range) | 178 (56–367) | 224 (113–418) | 0.01a |
Median ALT - U/L (range) | 71 (22–980) | 64 (19–1087) | 0.48a |
Median INR (range) | 1.1 (0.9–1.4) | 1.0 (0.9–1.2) | 0.69a |
HCV treatment outcomes | |||
№ Patients with rapid viral response (%) | 4 (15) | 12 (25) | 0.34b |
№ Patients with complete early viral response (%) | 9 (35) | 26 (54) | 0.11b |
№ Patients with end of treatment response (%) | 12 (46) | 24 (50) | 0.75b |
№ Patients with sustained viral response (%) | 9 (35) | 21 (44) | 0.45b |
№ Patients who discontinued HCV therapy due to non-viral response (%) | 8 (31) | 9 (19) | 0.24b |
№ Patients who discontinued HCV therapy due to treatment-related side effects (%) | 4 (15) | 14 (29) | 0.16b |
№ Patients lost to follow-up (%) | 2 (8) | 4 (8) | 0.92b |